SCHEMBL7033282

SCHEMBL7033282

COc1ccc(N)cc1C1=CCN(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
QDPR P09417 2/20 0.56
EHMT2 Q96KQ7 3/20 0.51
EHMT1 Q9H9B1 3/20 0.51
SLC6A4 P31645 2/20 0.47
TGFBR1 P36897 1/20 0.46
ACVR1 Q04771 1/20 0.46
CCNT1 O60563 1/20 0.45
CDK9 P50750 1/20 0.45
TLR9 Q9NR96 1/20 0.43
TLR8 Q9NR97 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7030177 1.00 QDPR (0.56) QDPREHMT2EHMT1SLC6A4TGFBR1
SCHEMBL6918514 0.82 KDM4E (0.45) QDPREHMT2EHMT1SLC6A4CCNT1
SCHEMBL428735 0.81 SLC6A4 (0.48) QDPRSLC6A4KDM4E
SCHEMBL27977286 0.80 QDPR (0.55) QDPREHMT2EHMT1SLC6A4TGFBR1
SCHEMBL7035799 0.80 QDPR (0.50) QDPREHMT2EHMT1SLC6A4TGFBR1
SCHEMBL5008338 0.79 SLC6A4 (0.48) QDPRSLC6A4
SCHEMBL29974417 0.79 QDPR (0.46) QDPRSLC6A4KDM4E
SCHEMBL5547709 0.79 QDPR (0.54) QDPRSLC6A4TGFBR1ACVR1KDM4E
SCHEMBL30108183 0.78 QDPR (0.50) QDPREHMT2EHMT1SLC6A4TGFBR1
SCHEMBL25565756 0.78 KDM4E (0.47) QDPRSLC6A4KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments SMITHKLINE BEECHAM P.L.C. 2003-04-10 US claimed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP claimed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO claimed
US-6599904-B2 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-29 US disclosed
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments SMITHKLINE BEECHAM P.L.C. 2003-04-10 US disclosed
US-6423717-B1 NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-23 US disclosed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP disclosed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments TPMT, MPST, STS QDPR 76/4885EHMT2 1740/4885EHMT1 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.